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Objective/background: The benefit of Continuous Positive Airway Pressure (CPAP) treatment following
ischemic stroke in patients with obstructive sleep-disordered breathing (SDB) is unclear. We set out to
investigate this open question in a randomized controlled trial as part of the SAS-CARE study.
Patients/methods.: Non-sleepy patients (ESS < 10) with ischemic stroke or transient ischemic attack (TIA)
and obstructive SDB (AHI  20) 3 months post-stroke were randomized 1:1 to CPAP treatment (CPAPþ)
or standard care. Primary outcome was the occurrence of vascular events (TIA/stroke, myocardial
infarction/revascularization, hospitalization for heart failure or unstable angina) or death within 24
months post-stroke. Secondary outcomes included Modified Rankin Scale (mRS) and Barthel Index.
Results: Among 238 SAS-CARE patients 41 (17%) non-sleepy obstructive SDB patients were randomized
to CPAP (n ¼ 19) or standard care (n ¼ 22). Most patients (80%) had stroke and were males (78%), mean
age was 64 ± 7 years and mean NIHSS score 0.6 ± 1.0 (range: 0e5). The primary endpoint was met by one
patient in the standard care arm (a new stroke). In an intent-to treat analysis disregarding adherence,
this corresponds to an absolute risk difference of 4.5% or an NNT ¼ 22. mRS and Barthel Index were stable
and similar between arms. CPAP adherence was sufficient in 60% of evaluable patients at month 24.
Conclusion: No benefit of CPAP started three months post-stroke was found in terms of new cardio- and
cerebrovascular events over 2 years. This may be related to the small size of this study, the mild stoke
severity, the exclusion of sleepy patients, the delayed start of treatment, and the overall low event rate.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).pital) and University of Bern,
rn, Switzerland.
assetti).
r B.V. This is an open access article1. Introduction
Sleep-disordered breathing (SDB) has a high prevalence and
persistence over time after stroke or TIA (transient ischemic
attack) [1] and has been recognized as a potentially modifiable
risk factor for cardio- and cerebrovascular morbidity andunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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identified as an independent risk factor for acute cerebrovascular
events. Both, OSA and central sleep apnea (CSA) are common in
patients with incident stroke or TIA, but, as for the general pop-
ulation, OSA is the most frequently reported SDB pattern in the
context of stroke.
Stroke has been reported to worsen a pre-existing SDB or even
induce this condition [2,3]. Also, SDB, and its severity, has been
associated with unfavorable stroke outcomes [4e9]. Intermittent
oxygen desaturations caused by OSA is assumed to be at the origin
of oxidative stress and systemic inflammation, which in turn have
been implicated in cardiovascular, metabolic as well as cognitive
complications [10]. Possibly also due to the association with the
presence of a patent foramen ovale, cardiac arrhythmias and hy-
percoagulability, OSA doubles the risk of stroke [11]. Regardless of
epidemiological and experimental evidence, the value of SDB and
OSA treatment by means of CPAP in patients with cardiovascular
diseases remains controversial. Promising results were obtained
in primary prevention. Longitudinal cohort studies pointed to a
reduced risk of cerebral and heart ischemia [12e14] but ran-
domized controlled evidence was less convincing [15]: a large
study in OSA patients without daytime sleepiness failed to
demonstrate a reduction in the incidence of hypertension or car-
diovascular events except for about one third of patients with an
adherence to CPAP >4 h/night. Findings from studies of secondary
prevention were less clear. While some benefit appeared to be
present in observational studies [16], according to a recent ran-
domized study [17] and a meta-analysis [5] a significant benefit
appears to be missing or only marginally significant for recurrent
strokes in those patients who were adherent [17]. However, spe-
cifically in stroke, data from the literature suggest a more favor-
able effect as a recent meta-analysis of 10 randomized studies
including less than 1000 patients [18]. However, samples were
heterogenous, methodologies and outcomes were assessed
differently and in all but 3 studies, randomized patients were
followed up for 3 months or less.
A recent statement of the European Neurology, Pulmonology,
Sleep, and Stroke Societies [19] has come to a similar conclusion,
while emphasizing the existence of a bidirectional relationship
between sleep and stroke and stressing the need for further
mechanistic and therapeutic investigations.
Here we present results from SAS-CARE 2, a randomized study
investigating the effect of CPAP started three months after stroke or
TIA on post-event clinical outcomes over a period of two years. This
project was part of SAS-CARE (Sleep Disordered Breathing in
Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous
Positive Airway Pressure (CPAP) Treatment Efficacy), a larger
research initiative about sleep in stroke patients, which included in
addition an observational study of patients who did not qualify for
participation in the randomized study and a prospective poly-
somnographic investigation about the prevalence and 3-month
evolution of SDB in stroke and TIA patients [20].2. Material and methods
The design of the international SAS-CARE investigator-initiated
study has been reported elsewhere [20]. The study (Clinical-
Trials.gov identifier: NCT01097967) was performed in Switzerland
(Bern, Lugano), Germany (Münster) and Italy (Milano). It was
approved by the local ethics committees and conducted in accor-
dance with the principles of good clinical practice and local regu-
lations. The SAS-CARE-2 investigation was approved as part of the
entire SAS-CARE project. It includes the randomized 2-parallel arm
study presented in this report.2
2.1. Participants
Between 29 September 2010 and 2 April 2014, we included
patients who provided written informed consent, were aged be-
tween 35 and 75 years, had experienced an acute TIA or ischemic
stroke requiring admission to a stroke unit within the last 60e90
days with appropriate diagnostic imaging (MRI or CT scan), and had
an evaluable nocturnal polysomnography (PSG) at approximately 3
months after stroke. Exclusion criteria were: unstable clinical
condition (cardio-respiratory or life-threatening medical condi-
tions), current CPAP treatment or other SDB treatment during the
last 3 months before stroke, non-ischemic events (intracerebral/
subarachnoid hemorrhage), coma/stupor and any condition that
may interfere with the acceptance of CPAP treatment. Randomi-
zation criteria additionally required patients to have moderate-to-
severe OSA, defined as AHI  20 [21] in the PSG at 3 months post-
stroke and to be non-sleepy as assessed by a score of <10 on the
Epworth Sleepiness Scale (ESS). Patients not included in the ran-
domized study were still included in the observational follow up
and evaluated for the primary outcome. Those with moderate-to-
severe SDB but who were sleepy were treated with CPAP within
the clinical routine. The last patient left the study on 28 April 2016.
All PSG recordings (titanium; Embla Flaga, Reykjavik, Iceland)
included six EEG channels, submental EMG, electro-oculogram,
nasal airflow, 2 channels of breathing effort and oximetry, and
EMG of both tibialis anterior muscles. PSGs after 3 months were
recorded in the sleep laboratory between 10 pm and 8 am. All re-
cordings were scored centrally and manually according to the
AASM 2012 international criteria [22]. Hypopneas were scored
when the peak signal excursions dropped by 30% of pre-event
baseline for 10 s in association with either 3% arterial oxygen
desaturation or an arousal. We did not differentiate between cen-
tral and obstructive hypopneas. SDBwas considered as OSA, if more
than 50% of the apneas were of obstructive origin, while, in case of
more than 50% of central apneas, SDB was classified as central.
2.2. Randomization and study treatment
Non-sleepy OSA patients with an AHI  20 in the PSG at 3
months post-stroke were randomized 1:1 to CPAP treatment
(CPAPþ arm) or no CPAP treatment (CPAP arm) without stratifi-
cation, using a computer-generated randomization list produced by
the coordinating center. In the CPAP arm, patients received an auto-
CPAP device. The initial setting range of pressurewas 7e14 cmH2O;
afterward the pressure could be adapted according to local clinical
practice to achieve optimal control of OSA.
2.3. Outcomes
Primary outcome was the occurrence of new vascular events
(TIA/stroke, myocardial infarction/revascularization, hospitaliza-
tion for heart failure, or unstable angina) or death (vascular or non-
vascular) in the 24 months after stroke.
Secondary outcomes were the occurrence of the events defining
the primary endpoint within 12 months post-event, Modified
Rankin Scale (mRS) at 12 and 24 months and functional indepen-
dence (mRS < 3) at 12 and 24 months.
Additional information collected in the study were location and
etiology of stroke based on the criteria of the TOAST-study [23],
stroke/TIA severity according to the National Institute of Health
stroke scale (NIHSS) [24] on admission.
Adherence to CPAP treatment was assessed at each of the
planned visits at 2e3 weeks, 4e6 weeks, 3e6, 12 and 24 months
after randomization. Adherence was classified as good if the device
was used for 5 h per night in at least 70% of the nights. Sufficient
C. Bernasconi, S.R. Ott, F. Fanfulla et al. Sleep Medicine: X 2 (2020) 100027adherence was defined for a use of CPAP for at least 4 h per night
during at least 70% of the nights. Insufficient adherencewas defined
as CPAP use <4 h per night or less than 70% of nights.
2.4. Statistical analysis
The sample size calculation assumed event rates at 2 years of
10% and 20% in the CPAPþ and CPAP arms, respectively. A total of
220 patients were expected to be randomized to provide a power of
80% for a two-sided test at the 5% significance level. Recruitment
was prematurely discontinued in April 2014 after an assessment
performed by the study management team indicated that the
overall event rate was clearly lower than anticipated, and that the
study would have required an extension clearly beyond the plan-
ned time frame.
The primary analysis was based on the intent-to-treat popula-
tion, including all randomized patients allocated to treatment arms
according to randomization. Missing values were not imputed and
sensitivity analyses were performed with different imputation
rules. Fisher's exact test was used to compare groups for categorical
variables and the Wilcoxon rank-sum test for continuous variables
and Wilcoxon signed-rank test. All statistical tests were two sided
and conducted at the 5% significance level without adjustment for
multiplicity.
3. Results
3.1. Patient disposition and baseline characteristics
As displayed in Fig. 1, out of 240 patients screened for the
different parts of the SAS-CARE study, 238 were included in the
observational follow up (one did not provide informed consent and
one did not have an evaluable PSG). Of those patients, 52 (22%)
displayed moderate-to-severe OSA in the PSG three months after
stroke, and 41 (17%) were non-sleepy and therefore eligible for
randomization into the treatment or control arms of SAS-CARE 2.
All received the intended treatment and were analyzed according
to the treatment arm defined by randomization. Most patients
were randomized in one of the two main study centers Bern and
Lugano, providing 49% and 39% of randomized patients, respec-
tively. Study completion rates were 82% and 84% in CPAP and
CPAPþ, respectively, with seven patients (CPAP n ¼ 4,
CPAPþ n ¼ 3) being lost to follow-up.
Non-randomized patients (n ¼ 197, 83%), who had either
AHI < 20 or were sleepy, were also followed up in parallel to the
randomized cohort. Sleepy patients with at least moderate OSA
(n ¼ 11, 5%) were treated with CPAP as per clinical practice.
Key background characteristics of randomized patients (ITT
population), including clinical presentation and treatment, are
shown in Table 1.
Most patients (74%) were included following an ischemic stroke,
and a slightly larger number of TIA patients was assigned to CPAP (3
vs. 5, resulting in an almost double proportion). Otherwise, baseline
characteristics appeared well balanced between the two treatment
arms. In general, events were of rather modest severity even in the
subset of patients with a stroke at study entry (mean mRS in stroke
patients 0.73 ± 0.75 and mean NIHSS 0.65 ± 1.12).
Compared to randomized patients, the observational non-
randomized cohort had slight differences: patients were more
often female (28%), younger (mean age 60.8 ± 9.5 years) had less
frequently a TIA (13.1%), and a more severe stroke (NIHSS
0.86 ± 1.58, mRS 0.79 ± 0.87, respectively) and similar BMI
(27.3 ± 4.6). Their Essen stroke risk score (1.9 ± 1.3) was lower. The
mean AHI was 11.4 ± 13.2/h, and 37.9 ± 15.2/h for the small group of
sleepy patients with moderate to severe SDB.3
3.2. Primary endpoint
The key results are presented in Table 2. Within the study period
of 18months following randomization (2 years after the stroke) one
new event was registered in the randomized patients: one recur-
rent ischemic stroke was reported at the month 12 visit in a 71-
year-old female patient from the CPAP arm who had initially
suffered a large artery stroke. The overall event rate (95% Clop-
perePearson CI) was 2.4% (0.1%e12.9%), and the event rate in the
CPAP arm was 4.5% (0.1%e22.8%). No death occurred. No statis-
tically significant between-arm difference (p > 0.7 in all tests) was
detected, neither in the primary analysis that did not impute
missing outcome data, nor in supportive analysis where patients
with unknown outcome were either evaluated as a separate cate-
gory or considered as havingmet the primary endpoint (event rates
22.7% and 15.8% in CPAP and CPAPþ, respectively, risk ratio with
95% CI: 0.695 [0.191, 2.532]).
Among 150 patients from the non-randomized cohort whowere
evaluable for the primary endpoint, the event rate was 10.6% (16
events). In 7 of the sleepy patients who exhibited moderate to se-
vere OSA, received CPAP treatment and were evaluable for the
primary endpoint (at inclusion there were 11 such patients), the
event rate was 28.6% (2 events).
3.3. Secondary endpoints
The level of disability among randomized patients, as measured
by the mRS and the Barthel index at month 12 and 24 (Table 3) was
in general rather low and not different between the two treatment
arms (mRS: p > 0.5 for all comparisons) for both timepoints. Fig. 2
shows the mRS as a categorical variable. The patient who met the
primary endpoint was the only one with a mRS>2 among the
randomized patients.
In the cohort of non-randomized patients, the mean mRS at
week was minimally lower (0.60 ± 0.74).
3.4. Adherence to CPAP treatment
As summarized in Table 4, among patients who were evaluated,
good adherence was the most common reported category (50%e
79% of patients). However, it has to be noted that an assessment
was not performed in a relevant proportion of CPAPþ patients: at
the initial assessment (Week 3e4) 80% of CPAPþ patients were
evaluable for adherence and this proportion progressively
decreased to 53% at month 24.
4. Discussion
The key observation from our study is that the overall rate of
new cardio or cerebrovascular events in the 2 years following the
initial ischemic cerebrovascular event was very small: only one
event was reported with an overall event rate of 2.4% among ran-
domized patients and 3.0% among those who were evaluable. The
overall disability level was also low.
Given that the observation timewas rather long and that the key
endpoints were of clinical nature, a potential clinical implication of
a low event rate is that CPAP treatment may not be useful for
secondary cardiovascular prevention in non-sleepy patients with
very mild strokes or TIA if started three months after stroke/TIA.
However, we cannot exclude potential benefits on an even longer
time scale. Given the small sample size and small variability in our
sample, our ability to make predictions beyond the study horizon
by means of statistical modeling is restricted. In addition, we
cannot exclude benefits in clinical domains we did not explicitly
assess as eg improvement of cognitive function [25]. For future
Fig. 1. Patient disposition.
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sufficient number of patients with severe residual symptoms and
high recurrence risk who would be still willing to participate in a
clinical investigation of this kind.
The low event rate and mild disability level can be in part
attributable to the predominantly mild stroke severity and the
young age in our patient population. On the other hand, in 150
patients who were observed outside the randomized study and
evaluable for the primary endpoint, the event rate was larger
(10.6%). Of note, in a small subgroup of these patients who
exhibited a moderate to severe SDB but were sleepy and therefore
assigned to CPAP treatment, two events were observed (event rate
28.6%). The higher event rate in non-randomized patients, who
had roughly the same risk profile as randomized patients except
for SDB and sleepiness, casts doubts on the representativeness of
the findings of the randomized study. Also, it constitutes a severe
limiting factor when it comes to the interpretation of the negative
study results in terms of effect size for the intervention under
investigation (no evidence for a difference between the two
treatment arms neither for primary nor for secondary outcomes).
Among prospective investigations with a design comparable to
ours and a sufficient follow-up for clinical events, a recent study
[26] reported an overall event rate of 10% at 12 months in 70
patients, who were, however, in clearly worse conditions at
baseline (mean mRS 1.95). Similar statements regarding baseline
characteristics and outcomes can be made for studies of CPAP for
stroke or TIA patients with obstructive sleep apnea [27]. In a4
randomized study of nasal CPAP, that also included patients with a
clear higher mean mRS (approximately 2.5) the event rate at 2
years was approximately 10% [28]. The apparent discrepancy in
the key findings among patient groups may be in relationwith the
small sample size of our study: the statistical precision of the
computed event rates is in fact small, with the upper limit of the
95%-CI exceeding 20% for primary endpoint in the CPAP arm.
Stated differently, given the overall low observed event rates, the
recruited sample would have provided a very low statistical po-
wer to detect even rather large effects in the randomized study,
for instance <20% power for event rates of 5% vs. 20%. The level of
certainty of our findings is therefore rather small. Based on the
primary event rate, assignment to CPAP in sleepy SDB patients,
despite the absence of a proper control group, did also not appear
to be beneficial.
Additional limitations need to be mentioned. Firstly, there were
somemissing data for the primary and secondary endpoints mainly
due to loss to follow-up. However, despite being slightly more
frequent in CPAP patients, loss to follow-up did not substantially
affect the significance of the treatment effect. Also, congestive heart
failure was not monitored systematically by echocardiography,
preventing an assessment of the impact of CPAP on central respi-
ratory effects. It also has to be considered that CPAP use does not
necessarily reflect a sufficient control of OSA. We aimed to control
SDB but cannot corroborate this with objective data, such as re-
sidual AHI. Finally, the study was conducted in central Europe, with
a limited diversity in the patient population.
Table 1







TIA 3 (13.6%) 5 (26.3%) 8 (19.5%)
Clinical infarct type
No information 0 (0%) 4 (21.1%) 4 (9.8%)
LACI 4 (18.2%) 3 (15.8%) 7 (17.1%)
TACI 1 (4.5%) 1 (5.3%) 2 (4.9%)
PACI 8 (36.4%) 4 (21.1%) 12 (29.3%)
POCI 9 (40.9%) 7 (36.8%) 16 (39%)
Stroke etiology (TOAST)
No information 0 (0%) 1 (5.3%) 1 (2.4%)
Large artery 3 (13.6%) 1 (5.3%) 4 (9.8%)
Cardioembolic 7 (31.8%) 3 (15.8%) 10 (24.4%)
Small artery 5 (22.7%) 2 (10.5%) 7 (17.1%)
Dissection or other 1 (4.5%) 2 (10.5%) 3 (7.3%)
Unknown e evaluated 3 (13.6%) 5 (26.3%) 8 (19.5%)
Unknown e in evaluation 1 (4.5%) 1 (5.3%) 2 (4.9%)
>one 0 (0%) 1 (5.3%) 1 (2.4%)
Patent foramen ovale only 1 (4.5%) 2 (10.5%) 3 (7.3%)
Atherosclerosis < 50% 1 (4.5%) 0 (0%) 1 (2.4%)
Aorta plaque 0 (0%) 1 (5.3%) 1 (2.4%)
Thrombolysis 4 (18.2%) 2 (10.5%) 6 (14.6%)
Sex e male 17 (77.3%) 15 (78.9%) 32 (78%)
Age [years] 64.7 ± 6.6/63 (59; 76) 64.1 ± 6.7/63.5 (60; 69) 64.4 ± 6.6/63 (59; 69)
Body mass index [kg/m2] 27.5 ± 5.6/26.0 (23.1; 29.3) 28.9 ± 5.1/27.8 (25.0; 31.7) 28.0 ± 5.2/26.2 (23.7; 30.7)
Modified Rankin scale (numeric) 0.62 ± 0.80/0 (0; 1) 0.79 ± 0.63/1 (0; 1) 0.70 ± 0.72/1 (0; 1)
NIHSS total score 0.48 ± 1.12/0 (0; 1) 0.63 ± 0.96/0 (0; 1) 0.55 ± 1.04/0 (0; 1)
Barthel index 99.8 ± 1.1/100 (100; 100) 99.7 ± 1.2/100 (100; 100) 99.7 ± 1.2/100 (100; 100)
Essen stroke risk score 2.38 ± 1.36/2 (1; 4) 2.28 ± 1.27/2 (1.25; 3.75) 2.33 ± 1.3/2 (1; 4)
AHI [events/h] 32.0 ± 11.3/26.9 (23.0; 37.8) 36.7 ± 14.8/32.9 (25.0; 42.8) 34.3 ± 13.2/32.3 (23.5; 42.2)
mean O2 saturation [%] 92.4 ± 2.1/92.9 (90.3; 94.1) 92.7 ± 1.5/92.9 (92.2; 93.4) 92.6 ± 1.8/92.9 (91.7; 93.7)
Minimum O2 saturation [%] 80.7 ± 6.1/82.0 (76.0; 85.0) 82.1 ± 3.1/82.0 (80.0; 84.5) 81.3 ± 4.9/82.0 (79.0; 85.0)
Saturation Time <90% [min] 78.5 ± 99.7/24.2 (4.9; 156.2) 22.2 ± 33.7/8.6 (6.0; 25.0) 53.9 ± 82.1/14.9 (5.1; 48.7)
For categorical variables data are presented n (% of N in the group), for continuous variables as mean ± standard deviation/median (first quartile; third quartile). For variables
not reflecting characteristics of the stroke (type, etiology, treatment) baseline refer to the randomization visit. Abbreviations not defined elsewhere: LACI: lacunar infarct;
TACI: total anterior circulation infarct; PACI: partial anterior circulation infarct; POCI: posterior circulation infarct; TOAST: Trial of Org 10172 in acute stroke treatment.
Table 2
Primary endpoint for randomized non-sleepy patients with sleep-disordered







Yes 1 (4.5%) 0 (0%) 1 (2.4%)
No 17 (77.3%) 16 (84.2%) 33 (80.5%)
Unknown 4 (18.2%) 3 (15.8%) 7 (17.1%)
Table 3
Secondary efficacy endpoints at month 12 and 24.
Month 12
Modified Rankin scale (numeric) N (evaluable patients)
mean ± standard deviation
median (first quartile; third quartile)
Min; max
Barthelindex N (evaluable patients)
mean ± standard deviation
median (first quartile; third quartile)
Min; max
Month 24
Modified Rankin scale (numeric) n (evaluable patients)
mean ± standard deviation
median (first quartile; third quartile)
Min; max
Barthel index n (evaluable patients)
mean ± standard deviation
median (first quartile; third quartile)
Min; max
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Although largely incomplete, as for several other similar studies
[18], the assessment of adherence indicated that CPAP may be
acceptable to a large proportion of patients. Because no clinical
events were reported in CPAPþ patients we were unable to eval-
uate the role of adherence with respect to the CPAP effect on stroke
outcomes.CPAP CPAPþ All randomized
16 17 33
0.50 ± 0.63 0.53 ± 0.72 0.52 ± 0.67
0 (0; 1) 0 (0; 1) 0 (0; 1)
0; 2 0; 2 0; 2
16 17 33
99.4 ± 1.7 98.2 ± 5.0 98.8 ± 3.8
100 (100; 100) 100 (100; 100) 100 (100; 100)
95; 100 80; 100 80; 100
12 16 28
0.75 ± 1.4 0.56 ± 0.72 0.64 ± 1.06
0 (0; 1) 0 (0; 1) 0 (0; 1)
0; 5 0; 2 0; 5
12 15 27
94.2 ± 20.2 99.0 ± 2.8 96.9 ± 13.5
100 (100; 100) 100 (100; 100) 100 (100; 100)
30; 100 90; 100 30; 100
Fig. 2. mRS at month 24.
Table 4
Adherence to CPAP treatment over time in the CPAPþ arm.
All CPAPþ patients (N ¼ 19) CPAPþ patients
assessed for adherence
Assessed Not assessed Insufficient Sufficient Good
Week 3e4 15 (78.9%) 4 (21.1%) 6 (40.0%) 1 (6.7%) 8 (53.3%)
Month 3 14 (73.7%) 5 (26.3%) 3 (21.4%) 1 (7.1%) 10 (71.4%)
Month 6 14 (73.7%) 4 (26.3%) 2 (14.3%) 1 (7.1%) 11 (78.6%)
Month 12 12 (63.2%) 7 (36.8%) 2 (16.7%) 3 (25%) 7 (58.3%)
Month 24 10 (52.6%) 9 (47.4%) 1 (10%) 3 (30%) 6 (60%)
C. Bernasconi, S.R. Ott, F. Fanfulla et al. Sleep Medicine: X 2 (2020) 1000275. Conclusion
Our results do not provide support to the use of CPAP for the
secondary prevention of cardio- or cerebrovascular events over a
period of two years in non-sleepy SDB patients following a mild
stroke if CPAP is started 3 months after the event. Larger prospec-
tive controlled trials including more severe strokes are necessary to
address the effects of early SDB treatment and the need of SDB re-
evaluation in the chronic stroke phase in specific subgroups,
eg patients with predominant CSA.Conflict of interest
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